Development of a highly efficacious vaccinia-based dual vaccine against smallpox and anthrax, two important bioterror entities

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 42, 2010, Pages 18091-18096

  Merkel, Tod J ^a   Perera, Pin Yu ^b   Kelly, Vanessa K ^a   Verma, Anita ^a   Llewellyn, Zara N ^c   Waldmann, Thomas A ^d   Mosca, Joseph D ^e   Perera, Liyanage P ^d  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e JDM Technologies Inc   (United States)

Author keywords

Biodefense; Bioterrorism; IL 15

Indexed keywords

ANTHRAX VACCINE; UNCLASSIFIED DRUG; VACCINIA VACCINE; WYETH INTERLEUKIN 15 PROTECTIVE ANTIGEN VACCINE;

ANIMAL EXPERIMENT; ANTHRAX; ANTIBODY TITER; ARTICLE; BACILLUS ANTHRACIS; BIOLOGICAL WARFARE; DRUG EFFICACY; EXPERIMENTAL RABBIT; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SINGLE DRUG DOSE; VACCINIA;

ANIMALS; ANTHRAX VACCINES; ANTIBODY FORMATION; BACILLUS ANTHRACIS; BIOTERRORISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; INTERLEUKIN-15; MICE; RABBITS; SMALLPOX VACCINE; VACCINIA VIRUS;

BACILLUS ANTHRACIS; BACTERIA (MICROORGANISMS); MUS; ORYCTOLAGUS CUNICULUS; VACCINIA VIRUS; VARIOLA MAJOR VIRUS; VARIOLA VIRUS;

EID: 78149240553     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1013083107     Document Type: Article

References (35)

1. World Health Organization (1970) Health Aspects of Chemical and Biological Weapons: A Report of a WHO Group of Consultants (World Health Organization, Geneva, Switzerland).
2. Cieslak TJ, et al. (2000) Immunization against potential biological warfare agents. Clin Infect Dis 30:843-850. (Pubitemid 32250320)
3. Russell PK (2007) Project BioShield: What it is, why it is needed, and its accomplishments so far. Clin Infect Dis 45(Suppl 1):S68-S72.
4. Mair M (2007) Recent progress in biodefence countermeasure development. Biosecur Bioterror 5:93-96. (Pubitemid 47170029)
5. Fenner F, Henderson DA, Arita I, Jecek Z, Ladnyi ID (1998) Smallpox and Its Eradication History of International Public Health (World Health Organization, Geneva, Switzerland).
6. Fenner F (1989) Risks and benefits of vaccinia vaccine use in the worldwide smallpox eradication campaign. Res Virol 140:465-466, discussion 487-491.
7. Greenberg RN, Kennedy JS (2008) ACAM2000: A newly licensed cell culture-based live vaccinia smallpox vaccine. Expert Opin Investig Drugs 17:555-564.
8. Frankel AE, et al. (2009) Pathophysiology of anthrax. Front Biosci 14:4516-4524.
9. Henderson DW, Peacock S, Belton FC (1956) Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J Hyg (Lond) 54:28-36.
10. Friedlander AM, Little SF (2009) Advances in the development of next-generation anthrax vaccines. Vaccine 27(Suppl 4):D28-D32.
11. Perera LP, et al. (2007) Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice. J Virol 81:8774-8783.
12. Zielinski RJ, et al. (2010) Smallpox vaccine with integrated IL-15 demonstrates enhanced in vivo viral clearance in immunodeficient mice and confers long term protection against a lethal monkeypox challenge in cynomolgus monkeys. Vaccine, 10.1016/j.vaccine.2010.08.008.
13. Lee JS, Hadjipanayis AG, Welkos SL (2003) Venezuelan equine encephalitis virus-vectored vaccines protect mice against anthrax spore challenge. Infect Immun 71:1491-1496.
14. McConnell MJ, Hanna PC, Imperiale MJ (2006) Cytokine response and survival of mice immunized with an adenovirus expressing Bacillus anthracis protective antigen domain 4. Infect Immun 74:1009-1015.
15. Verma A, et al. (2008) Role of the N-terminal amino acid of Bacillus anthracis lethal factor in lethal toxin cytotoxicity and its effect on the lethal toxin neutralization assay. Clin Vaccine Immunol 15:1737-1741.
16. Pittman PR, et al. (2005) Protective antigen and toxin neutralization antibody patterns in anthrax vaccinees undergoing serial plasmapheresis. Clin Diagn Lab Immunol 12:713-721.
17. Little SF, et al. (2004) Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 22:422-430.
18. Pitt MLM, et al. (2001) In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 19:4768-4773.
19. Livingston BD, Little SF, Luxembourg A, Ellefsen B, Hannaman D (2010) Comparative performance of a licensed anthrax vaccine versus electroporation based delivery of a PA encoding DNA vaccine in rhesus macaques. Vaccine 28:1056-1061.
20. Welkos S, Little S, Friedlander A, Fritz D, Fellows P (2001) The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology 147:1677-1685. (Pubitemid 32544833)
21. Stepanov AV, Marinin LI, Pomerantsev AP, Staritsin NA (1996) Development of novel vaccines against anthrax in man. J Biotechnol 44:155-160. (Pubitemid 26056574)
22. Cote CK, et al. (2005) The detection of protective antigen (PA) associated with spores of Bacillus anthracis and the effects of anti-PA antibodies on spore germination and macrophage interactions. Microb Pathog 38:209-225.
23. Schumacher WC, Storozuk CA, Dutta PK, Phipps AJ (2008) Identification and characterization of Bacillus anthracis spores by multiparameter flow cytometry. Appl Environ Microbiol 74:5220-5223.
24. Loving CL, Kennett M, Lee GM, Grippe VK, Merkel TJ (2007) Murine aerosol challenge model of anthrax. Infect Immun 75:2689-2698. (Pubitemid 46870149)
25. Graham B, et al. (2008) World at Risk: The Report on the Commission on the Prevention of WMD Proliferation and Terrorism (Vintage Books, New York), 132pp.
26. IOM Committee to Assess the Safety and Efficacy of the Anthrax Vaccine (2002) The Anthrax Vaccine: Is It Safe? Does It Work? (National Academies Press, Washington, DC).
27. Buller RML, Palumbo GJ (1992) Safety and attenuation of vaccinia viruses. Recombinant Poxviruses, eds Binns MM, Smith GL (CRC Press, Boca Raton, FL), pp 235-267.
28. Waldmann TA (2006) The biology of interleukin-2 and interleukin-15: Implications for cancer therapy and vaccine design. Nat Rev Immunol 6:595-601. (Pubitemid 44134092)
29. Rochman Y, Spolski R, Leonard WJ (2009) New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 9:480-490.
30. Bernasconi NL, Traggiai E, Lanzavecchia A (2002) Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298:2199-2202.
31. Oh S, Berzofsky JA, Burke DS, Waldmann TA, Perera LP (2003) Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. Proc Natl Acad Sci USA 100:3392-3397.
32. Oh S, Perera LP, Burke DS, Waldmann TA, Berzofsky JA (2004) IL-15/IL-15Ralpha-mediated avidity maturation of memory CD8+ T cells. Proc Natl Acad Sci USA 101:15154-15159.
33. Iacono-Connors LC, Welkos SL, Ivins BE, Dalrymple JM (1991) Protection against anthrax with recombinant virus-expressed protective antigen in experimental animals. Infect Immun 59:1961-1965.
34. Earl PL, Moss B, Wyatt LS, Carroll MW (2001) Generation of recombinant vaccinia viruses. Curr Protoc Protein Sci, 5.13.1-5.13.19.
35. Welkos SL, et al. (1988) Sequence and analysis of the DNA encoding protective antigen of Bacillus anthracis. Gene 69:287-300.